Cours suspendu

Communiqués Day One Biopharmaceuticals, Inc.

Actions

DAWN

US23954D1090

Produits pharmaceutiques

Temps Différé Nasdaq 22:00:00 22/04/2026			Varia. 5j.	Varia. 1 janv.
21,53 ^USD	+0,19%		-.--%	+131,01%

08/05	Day One Biopharmaceuticals annonce la fin du recrutement pour l'essai pivot de Phase 3 FIREFLY-2 évaluant le tovorafenib en traitement de première ligne du gliome pédiatrique de bas grade	CI
23/04	Day One Biopharmaceuticals, Inc. annonce des changements au sein de sa direction	CI

Communiqués

23/04	Servier completes the acquisition of Day One Biopharmaceuticals	AQ
26/03	Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN	BU
07/03	Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN	BU
06/03	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)	NE
06/03	Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio	GL
24/02	Day One Biopharmaceuticals : Q4 2025 Earnings Call	PU
24/02	Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance	AQ
10/02	Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026	AQ
11/01	Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance	AQ
16/12	Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
25/11	Day One Announces Three Year Follow-Up Data from OJEMDA Phase 2 FIREFLY-1 trial at the 2025 Society for Neuro-Oncology Annual Meeting	AQ
24/11	Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting	GL
18/11	Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference	GL
13/11	Day One Biopharmaceuticals : Acquisition of Mersana Therapeutics	PU
13/11	Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases	GL
10/11	Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting	GL
04/11	Day One Biopharmaceuticals : Q3 2025 Earnings Call Presentation (1)	PU
04/11	Day One Reports Third Quarter 2025 Financial Results and Corporate Progress	GL
21/10/25	Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025	GL
05/08/25	Day One Biopharmaceuticals : Q2 2025 Earnings Call (1)	PU
05/08/25	Day One Reports Second Quarter 2025 Financial Results and Corporate Progress	GL
22/07/25	Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025	GL
11/06/25	Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development	AQ
10/06/25	Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development	GL
07/05/25	Day One Biopharmaceuticals : Q1 2025 Earnings Call	PU